Asensus Surgical (Asensus Surgical) Operating Income : $-78.13 Mil (TTM As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is Asensus Surgical Operating Income?

Asensus Surgical's Operating Income for the three months ended in Dec. 2023 was $-15.33 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-78.13 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Asensus Surgical's Operating Income for the three months ended in Dec. 2023 was $-15.33 Mil. Asensus Surgical's Revenue for the three months ended in Dec. 2023 was $5.43 Mil. Therefore, Asensus Surgical's Operating Margin % for the quarter that ended in Dec. 2023 was -282.34%.

Warning Sign:

Asensus Surgical Inc operating margin has been in a 5-year decline. The average rate of decline per year is -16.4%.

Asensus Surgical's 5-Year average Growth Rate for Operating Margin % was -16.40% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Asensus Surgical's annualized ROC % for the quarter that ended in Dec. 2023 was -193.39%. Asensus Surgical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -404.58%.

Asensus Surgical Operating Income Historical Data

The historical data trend for Asensus Surgical's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asensus Surgical Operating Income Chart

Asensus Surgical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Income

Get a 7-Day Free Trial

-91.74

-56.61

-66.18

-75.36

-78.13

Asensus Surgical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Income	Get a 7-Day Free Trial															-17.08	-22.24	-20.66	-19.89	-15.33

Asensus Surgical Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-78.13 Mil.

Asensus Surgical (AMEX:ASXC) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Asensus Surgical's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-61.336 * ( 1 - -1.04% )	/	( (31.854	+	32.238)	/ 2 )
=	-61.9738944	/	32.046
=	-193.39 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	70.727	-	5.784	-	( 33.089	-	max(0, 12.123	-	45.932	+	33.089	))
=	31.854

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	59.086	-	5.781	-	( 21.067	-	max(0, 12.628	-	36.386	+	21.067	))
=	32.238

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Asensus Surgical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-68.228	/	( ( (14.241 + max(1.636, 0))	+	(14.124 + max(3.727, 0)) )	/	2 )
=	-68.228	/	( ( 15.877	+	17.851 )	/	2 )
=	-68.228	/	16.864
=	-404.58 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.662	+	6.683	+	5.498)	-	(5.784	+	0.456	+	4.967)
=	1.636

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(3.508	+	7.172	+	4.639)	-	(5.781	+	0.421	+	5.39)
=	3.727

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Asensus Surgical's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-15.334	/	5.431
	=	-282.34 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Asensus Surgical Operating Income Related Terms

Thank you for viewing the detailed overview of Asensus Surgical's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Asensus Surgical (Asensus Surgical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Asensus Surgical Inc (AMEX:ASXC) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

2TX:Germany

Address

1 TW Alexander Drive, Suite 160, Durham, NC, USA, 27703

Website

https://www.asensus.com

Asensus Surgical Inc is a medical device company that digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seeks to address the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System is the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world. The company's single segment includes the research, development, and sale of medical device robotics to improve minimally invasive surgery.

Executives

Starling William N Jr	director	2300 BUCKSKIN ROAD, POCATELLO ID 83201
Andrea Biffi	director	C/O SOFAR SPA, VIA FIRENZE 40, TREZZANO ROSA (MI) L6 20060
Elizabeth Kwo	director	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
David Bruce Milne	director	ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Kevin J Hobert	director	343 STATE STREET, ROCHESTER NY 14650
Fernando Anthony C. J.	officer: Chief Technology Officer	635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Rampertab Shameze	officer: EVP, Chief Financial Officer	C/O ZOMEDICA PHARMACEUTICALS CORP., 3928 VARSITY DRIVE, ANN ARBOR MI 48108
Brett Farabaugh	officer: Interim CFO	108 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709
Joseph P Slattery	officer: EVP and CFO	C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Eric A Smith	officer: Chief Commercial Officer	7 CALEB CIRCLE, SAN ANTONIO TX 78258
Todd Pope	director, officer: President and CEO	C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713
Willam N Kelley	director	MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889
Pfenniger Richard C Jr	director	4400 BISCAYNE BLVD., MIAMI FL 33137
Sofar, S.p.a	10 percent owner	VIA FIRENZE 40, TREZZANO ROSA L6 20060
Andrew N Schiff	director, 10 percent owner	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022